Recombinant Human Hyaluronidase PH20 in Biologics and Immunoglobulin Therapy:

Amy E. Clarke, DNP, RN, IgCN®Chief Clinical OfficerImmunoglobulin National SocietyCalabasas, CaliforniaLuba Sobolevsky, PharmD, IgCP®President and CEOImmunoglobulin National SocietyCalabasas, CaliforniaDavid Kang, BScDirectorHalozyme Therapeutics, IncSan Diego, CaliforniaMarie Printz, BAExecutive DirectorHalozyme Therapeutics, IncSan Diego, CaliforniaSubcutaneous (SC) delivery has become a preferred route across many therapeutic areas because it reduces reliance on infusion suites, shift